Pharma & Veterinary Briefing 2026: FDA Green Book Exclusivities, Advanced Manufacturing, and Key IP Decisions
Quick 2-minute reading
Pharma Regulatory & IP Digest: Veterinary Drug Exclusivities, Distributed Manufacturing, and Landmark D.C. Circuit Patent Ruling
Welcome to the Sidvim LifeSciences monthly briefing. This month, we cover key developments in the 2026 veterinary drug market, new USFDA manufacturing proposals, an impactful PBM lawsuit settlement, and a critical appellate decision regarding post-trial ANDA modifications.
1. USFDA Green Book 2026: A Deep Dive into Veterinary Drug Exclusivities
The veterinary medicine sector has seen approximately 16 animal drug approvals so far in 2026, encompassing 6 New Chemical Entities (NCEs) and 10 Lifecycle Management (LCM) expansions
The framework breaks down into two core exclusivity shields for New Animal Drug Applications (NADAs)
5-Year Exclusivity (NCE / Original NADA): Awarded when the active moiety has never before been approved by the FDA in an animal drug application
. During this timeline, the FDA is prohibited from approving an Abbreviated New Animal Drug Application (ANADA) copying that moiety . 3-Year Exclusivity (LCM / Supplemental NADA): Granted for changes to previously approved molecules where the sponsor conducted new clinical trials (beyond basic bioequivalence) essential to the approval
. It shields only the specific technological variation or new indication .
Key NADA Approvals Dashboard (2026)
Vetmedin (Pimobendan | Boehringer Ingelheim): Earned a 3-year exclusivity window (expiring Dec 19, 2028) for shifting from a chewable format to a liquid solution to maintain dog heart failure management market dominance
. NexGard (Afoxolaner | Boehringer Ingelheim): Secured 3 years of data protection (expiring Mar 16, 2029) for its blockbuster canine oral parasiticide to defend its billion-dollar retail share against rising generics
. CosACTHen (Cosyntropin | Dechra): Granted 5 years of NCE exclusivity (expiring Dec 19, 2030) as a synthetic ACTH analogue for evaluating canine adrenal function
. Numelvi (Atinvicitinib | Merck Animal Health): Captured 5 years of exclusivity (expiring Feb 25, 2031) as a first-in-class second-generation JAK1 inhibitor to tackle canine allergic dermatitis
. AMODIP (Amlodipine Besylate | Ceva Sante Animale): Acquired 5 years of exclusivity (expiring Apr 29, 2031) as the first chewable format cleared for feline systemic hypertension
. This illustrates how human generic active ingredients can secure NCE status even if they have never been approved for animal use . LAVERDIA (Verdinexor | Anivive): Obtained a 5-year runway (expiring Dec 18, 2030) for a novel oral canine lymphoma therapy
. KBROVET (Potassium Bromide | Pegasus): Granted 5 years of exclusivity (expiring Jan 09, 2031) for canine idiopathic epilepsy, replacing traditional pharmacy compounding
. Tessie (Tasipimidine | Orion): Awarded 5 years of safety data protection (expiring May 06, 2031) as the first behavioural therapeutic dual-cleared for noise aversion and separation anxiety
.
Regulatory Note: Unlike the human pharmaceutical landscape, generic animal filers submitting an ANADA under Section 512(n) do not have access to 180-day market exclusivity pathways
2. General Industry News
Distributed Drug Manufacturing Framework: The USFDA has introduced a comprehensive policy proposal outlining a new registration and listing pathway for distributed drug manufacturing
. The initiative seeks to stabilise the domestic commercial supply chain, enhance visibility into foreign facility tracking, and clear regulatory bottlenecks for innovative, decentralised production models. FTC Settles Insulin Pricing Suit with CVS Caremark: The Federal Trade Commission finalised a major settlement with pharmacy benefit manager (PBM) CVS Caremark over allegations of insulin price manipulation and restricted drug access
. The deal is projected to unlock approximately USD 8.5 billion in consumer out-of-pocket savings over 10 years and direct up to USD 4.5 billion back to patients via point-of-sale counter rebates .
3. Intellectual Property Spotlight
D.C. Circuit Decides Norwich Pharmaceuticals, Inc. v. Kennedy (Case No. 23-5311)
On June 26, 2026, the D.C. Circuit Court of Appeals affirmed a summary judgment ruling confirming that the FDA acted completely within the law when it refused to grant final commercial approval to Norwich’s modified generic product
Hoping to bypass the blockade, Norwich modified its application to strip out the infringing hepatic encephalopathy label, leaving only the non-infringing indications, and sued the FDA when the agency refused to upgrade its tentative approval to a final launch clearance
The D.C. Circuit flatly rejected Norwich's argument that the FDA misread the injunction
Furthermore, the court distinguished this from the landmark Ferring B.V. v. Watson Laboratories precedent
Key Strategy Lesson: Generic developers face immense risks if they attempt post-trial label modifications. If a carve-out strategy is not completed before the entry of a final judgment, a judicial order tied strictly to the underlying ANDA number can completely freeze the asset, forcing the company to wait until the patents expire or to absorb the immense delays and costs of filing a new ANDA number from scratch
-----------XX------------XX-----------------------
Contents
USFDA Green Book 2026: A Deep Dive into New Veterinary Drug Exclusivities
General information
FDA Proposes New Registration and Listing Pathway for Distributed Drug Manufacturing and Aligns Foreign Establishment Obligations With Current Law
FTC settles lawsuit with CVS Caremark over charges it manipulated insulin prices, impeded access
Intellectual Property
Summary of D.C. Circuit Decision: Norwich Pharmaceuticals, Inc. v. Kennedy
USFDA Green Book 2026: A Deep Dive into New Veterinary Drug Exclusivities
There have been approximately 16 veterinary drug approvals so far in 2026. These include New Chemical Entities and Life Cycle Management approvals. Specifically, there are 6 NCE approvals and 10 LCM approvals. For the former, one receives 5 years of exclusivity, and for the latter, 3 years of exclusivity. This is similar to the human drug approvals, which are governed by Section 505 of the Federal Food, Drug, and Cosmetic Act
For animal drugs, the entire legal framework is governed by Section 512 of the FD&C Act and administered by the Centre for Veterinary Medicine (CVM).
The distinction breaks down as follows:
The 5-Year Exclusivity Period (New Chemical Entities/ NADA)
- Granted only to original applications (not supplements) where the active moiety (the active molecule responsible for the physiological or pharmacological action) has never been approved before by the FDA in an animal drug application. In AMODIP, Amlodipine was approved for human use but not for veterinary use, and one would notice it sought 5 years of exclusivity as it was never approved by the FDA for animal use.
- During these 5 years, the FDA cannot approve an ANDA that copies this active moiety.
- The 3-Year Exclusivity Period (Lifecycle Management / Changes/ Supplementary NADA)
- Granted to original or supplemental applications for a molecule that has already been previously approved, but the sponsor has conducted new clinical investigations (other than simple bioequivalence or residue depletion studies) that were essential to secure the new approval.
- It protects only the specific change or innovation that requires the new clinical trial data.
Examples from the 2026 list below:
- Vetmedin Solution (3 years): The API (pimobendan) is already a massive blockbuster block, but switching from a chewable tablet to a liquid solution required new technical/clinical validation data.
- NexGard PLUS / Bravecto Quantum (3 years): These leverage existing, well-known APIs (afoxolaner, fluralaner) but offer brand-new combo configurations or an extended 12-month delivery mechanism.
These exclusivities are available for NADA applicants.
Abbreviated New Animal Drug Application (ANADA)
Instead of a human generic application (ANDA), a veterinary generic filer submits an ANADA (Abbreviated New Animal Drug Application) under Section 512(n) of the FD&C Act. If an ANADA filer wants to make a permissible change (like a different strength or dosage form) to a reference drug, they must first submit a Suitability Petition to the CVM. If approved, they can proceed with an abbreviated application (ANADA) rather than full safety/efficacy trials.
ANADA applications do not receive market exclusivity. Furthermore, the veterinary framework does not provide 180-day market exclusivity like the human drug market in the USA does (P-IV challenges or CGT).
Please note that ANADA approvals are not included in the table below and are not part of this document. The table below covers NADA approvals since January 2026.
General information
FDA Proposes New Registration and Listing Pathway for Distributed Drug Manufacturing and Aligns Foreign Establishment Obligations With Current Law
FTC settles lawsuit with CVS Caremark over charges it manipulated insulin prices, impeded access
Intellectual Property
Summary of D.C. Circuit Decision: Norwich Pharmaceuticals, Inc. v. Kennedy
On June 26, 2026, the United States Court of Appeals for the District of Columbia Circuit issued its decision in Norwich Pharmaceuticals, Inc. v. Robert F. Kennedy, Jr. (Case No. 23-5311). The panel, consisting of Circuit Judges, affirmed the U.S. District Court for the District of Columbia’s grant of summary judgment in favour of the Food and Drug Administration (FDA) and intervenor Salix Pharmaceuticals, Inc.
The court held that the FDA did not act arbitrarily, capriciously, or contrary to law by refusing final approval of Norwich’s amended ANDA No. 214369. The D.C. Circuit concluded that a prior Delaware district court judgment explicitly barred the approval of that specific ANDA number until October 2029, regardless of any post-judgment amendments made to the application's labelling.
Case History and Originating Patent Litigation
Salix Pharmaceuticals developed and markets Xifaxan, a brand-name drug indicated for the treatment of irritable bowel syndrome with diarrhoea (IBS-D) and hepatic encephalopathy (a brain dysfunction caused by liver disease). Seeking to market a generic competitor, Norwich Pharmaceuticals submitted ANDA No. 214369 to the FDA.
Salix subsequently sued Norwich for patent infringement in the U.S. District Court for the District of Delaware. Following a trial, the Delaware court determined that Norwich’s ANDA infringed Salix's patents covering the hepatic encephalopathy indication, though it found Salix's IBS-D patents invalid as obvious.
During final judgment drafting under 35 U.S.C. § 271(e)(4)(A), Norwich requested language that would permit immediate FDA approval if it carved out the infringing hepatic encephalopathy labelling. The Delaware court rejected this, issuing a final order stating that the effective date of any final approval by the US FDA of Norwich's ANDA No. 214369 shall not be earlier than October 2, 2029.
Following the judgment, Norwich removed the hepatic encephalopathy indication from its application and filed a Rule 60(b) motion to modify the order. The Delaware court denied the motion, ruling that a party cannot litigate a case through trial on a specific ANDA and then alter it post-judgment to circumvent the ruling. The Federal Circuit later affirmed this decision, noting the order bound the entire ANDA but did not prevent Norwich from filing an entirely new non-infringing ANDA.
D.C. Circuit Analysis: Plain Meaning and Context
Because of the Delaware injunction, the FDA withheld final approval of Norwich’s amended '369 ANDA, issuing only a tentative approval. Norwich then sued the FDA in the D.C. District Court, claiming the agency misread the Delaware judgment. After losing at the district level, Norwich appealed to the D.C. Circuit.
Writing for the court, Circuit Judge focused heavily on the plain text of the Delaware judgment. The order explicitly identified Norwich's application by its unique designation "ANDA No. 214369" and barred its final approval before October 2, 2029. The D.C. Circuit concluded that because the amended application remains the '369 ANDA, the FDA's refusal to grant final approval directly tracked the most straightforward, plain-language reading of the judicial mandate.
The court emphasised that the surrounding litigation context strongly reinforced this plain text. Before the final judgment was entered, Norwich had explicitly asked the Delaware court to exclude an amended carve-out from the structural block, but the court flatly refused. Furthermore, in its subsequent Rule 60(b) motions, Norwich itself repeatedly acknowledged that the judgment acted as a "bottleneck" and an "absolute prohibition" preventing the FDA from approving its amended text. The D.C. Circuit stated that Norwich could not now argue that the judgment implicitly contained the very qualifying language the original court had explicitly rejected twice.
Distinguishing Judicial Precedent
Norwich attempted to rely on Ferring B.V. v. Watson Laboratories, Inc.- Florida (Fed. Cir. 2014), in which a post-trial ANDA amendment successfully mooted certain patent infringement concerns.
However, the D.C. Circuit distinguished the two cases based on the timing of the amendments. In Ferring, the generic manufacturer had actively stipulated and committed to amend its application during the trial itself. Conversely, Norwich fully litigated its case through a complete trial and final judgment based on its original, infringing ANDA specifications, attempting to alter its strategy only after receiving an adverse final ruling.
Conclusion and Key Takeaways
The D.C. Circuit concluded that the FDA acted properly under the law by delaying the final approval of ANDA No. 214369 until October 2029, regardless of Norwich's post-judgment labelling carve-outs.
For generic pharmaceutical developers, this ruling highlights the strategic risks of post-trial label changes. If a developer fails to update or exclude infringing indications before a final judgment, a judicial order strictly linked to the ANDA number can halt the application entirely, forcing the company to wait out the patent duration or incur high costs and delays to file a new ANDA.
Decision here
#PharmaRegulations #FDAUpdate #IntellectualProperty #PharmaPatents #GenericDrugs #GreenBook2026 #VeterinaryPharma #ANDALitigation #SidvimPharmaUpdate
